Here, we uncover that DCAF7 and USP2 expression are significantly elevated in HCC tissues and provide compelling evidence that genetic depletion of DCAF7 or pharmacological inhibition of USP2 sensitizes HCC to sorafenib and inhibits HCC progression both in vitro and in vivo. This evidence concerns the gene USP2 and hepatocellular carcinoma.